Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL J LEONARD IV

Allopathic & Osteopathic Physicians Pediatrics

NPI
1801058243
CMS profile
500103
Location
HASTINGS, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$33.08

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $33.08 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Supernus Pharmaceuticals, Inc. $20.49 1
PFIZER INC. $12.59 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL J LEONARD IV

NPI 1801058243 · CMS profile ID 500103

Allopathic & Osteopathic Physicians / Pediatrics

HASTINGS, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $33.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Supernus Pharmaceuticals, Inc. $20.4911/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053276887 CMS
PFIZER INC. $12.0509/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049130133 CMS
PFIZER INC. $0.5409/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050416791 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $13.39 1
PY2023 $33.08 3
PY2024 $109.51 4
PY2025 $27.88 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $168,874.99 57
PY2024 Principal investigator $439,732.84 105
PY2023 Recipient $7,049.40 6
PY2023 Principal investigator $530,880.36 269
PY2022 Principal investigator $1,225,410.93 120
PY2021 Principal investigator $1,389,610.75 61
PY2020 Principal investigator $5,537.42 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $772.50 12/31/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Less Than 2 Years of Age with Functional Constipation (FC). No dispute reported 06/30/2026 1202532424
Principal investigator 1 ABBVIE INC. $772.50 12/31/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, with Functional Constipation (FC) with a 24-week Open-label Treatment Extension No dispute reported 06/30/2026 1202532426
Principal investigator 1 Merck Sharp & Dohme LLC $2,060.78 12/31/2025 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1232921482
Principal investigator 1 Merck Sharp & Dohme LLC $39,714.81 12/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Grand Island
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1232933006
Principal investigator 1 ModernaTX, Inc. $626.00 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252985236
Principal investigator 1 ModernaTX, Inc. $1,357.00 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252985248
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252985250
Principal investigator 1 ABBVIE INC. $1,372.00 12/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1202530174
Principal investigator 1 GlaxoSmithKline, LLC. $1,273.12 12/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192104268
Principal investigator 1 GlaxoSmithKline, LLC. $988.00 12/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192104287
Principal investigator 1 ABBVIE INC. $5,718.00 11/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1202525374
Principal investigator 1 GlaxoSmithKline, LLC. $4,980.06 11/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192104262
Principal investigator 1 GlaxoSmithKline, LLC. $661.69 10/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192104282
Principal investigator 1 ABBVIE INC. $1,175.00 10/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202515989
Principal investigator 1 GlaxoSmithKline, LLC. $1.00 10/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192104293
Principal investigator 1 GlaxoSmithKline, LLC. $3,310.00 09/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192104256
Principal investigator 1 GlaxoSmithKline, LLC. $2,419.83 08/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192164526
Principal investigator 1 ModernaTX, Inc. $2,311.06 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252985238
Principal investigator 1 SANOFI PASTEUR INC. $1,376.20 07/25/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226092662
Principal investigator 1 ABBVIE INC. $1,863.00 07/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1202496155
Principal investigator 1 SANOFI PASTEUR INC. $5,531.75 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226092703
Principal investigator 1 ModernaTX, Inc. $1,500.00 06/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252985240
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252985246
Principal investigator 1 GlaxoSmithKline, LLC. $422.79 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192165084
Principal investigator 1 ABBVIE INC. $7,600.00 06/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202490751
Principal investigator 1 Merck Sharp & Dohme LLC $22,836.40 06/09/2025 Non-covered Recipient Entity
Velocity Clinical Research, Grand Island
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1232933004
Principal investigator 1 GlaxoSmithKline, LLC. $2,459.44 05/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192164501
Principal investigator 1 ModernaTX, Inc. $1,133.72 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252985228
Principal investigator 1 SANOFI PASTEUR INC. $1,376.20 04/16/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226093068
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 04/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192165089
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 04/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192165098
Principal investigator 1 ModernaTX, Inc. $237.19 03/26/2025 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252985232
Principal investigator 1 ModernaTX, Inc. $696.96 03/26/2025 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252985234
Principal investigator 1 ModernaTX, Inc. $1,200.00 03/26/2025 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252985244
Principal investigator 1 SANOFI PASTEUR INC. $984.20 03/26/2025 Non-covered Recipient Entity
Velocity Clinical Research
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114788
Principal investigator 1 SANOFI PASTEUR INC. $2,240.00 03/21/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226089347
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 03/21/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226089353
Principal investigator 1 SANOFI PASTEUR INC. $5,840.00 03/18/2025 Non-covered Recipient Entity
Velocity Clinical Research
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114814
Principal investigator 1 GlaxoSmithKline, LLC. $436.52 03/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192164522
Principal investigator 1 GlaxoSmithKline, LLC. $525.43 03/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192164496
Principal investigator 1 ABBVIE INC. $541.00 02/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202452843
Principal investigator 1 ABBVIE INC. $2,224.00 02/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202452847
Principal investigator 1 ABBVIE INC. $703.00 02/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202452850
Principal investigator 1 ModernaTX, Inc. $6,000.00 02/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1252985230
Principal investigator 1 ModernaTX, Inc. $6,000.00 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1252985242
Principal investigator 1 SANOFI PASTEUR INC. $577.15 02/19/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1226089335
Principal investigator 1 GlaxoSmithKline, LLC. $850.44 02/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192164517
Principal investigator 1 Merck Sharp & Dohme LLC $2,500.00 02/10/2025 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1232921480
Principal investigator 1 Amgen Inc. $2,612.52 01/30/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246651495
Principal investigator 1 GlaxoSmithKline, LLC. $282.98 01/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192165080
Principal investigator 1 GlaxoSmithKline, LLC. $16.75 01/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192164508
Principal investigator 1 GlaxoSmithKline, LLC. $262.58 01/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192164513
Principal investigator 1 SANOFI PASTEUR INC. $2,381.40 01/21/2025 Non-covered Recipient Entity
Velocity Clinical Research
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226115513
Principal investigator 1 GlaxoSmithKline, LLC. $3,542.86 01/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192165093
Principal investigator 1 GlaxoSmithKline, LLC. $426.71 01/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192104297
Principal investigator 1 GlaxoSmithKline, LLC. $2,288.77 01/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1192164505
Principal investigator 1 GlaxoSmithKline, LLC. $4,391.68 01/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1192104276